Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited (ASX: VLA, OTC: VRACY) announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK™, with MSD's KEYTRUDA®, an anti-PD-1 (programmed death receptor-1) therapy.

The Phase 1b clinical trial will evaluate the safety and efficacy of this novel immunotherapy combination in patients with either advanced stage non-small cell lung cancer (NSCLC) or metastatic bladder cancer. Viralytics, in collaboration with MSD, will be the sponsor of the study, which is planned to begin in 2016.

As members of a new class of cancer treatments known as immunotherapies, both CAVATAK and KEYTRUDA are designed to enhance the body's own defences in fighting cancer. CAVATAK is an investigational agent based on a proprietary bioselected common cold virus that has been shown to preferentially infect and attack cancer cells. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to help detect and fight tumour cells. KEYTRUDA blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, and may affect both tumour cells and healthy cells.

"We are excited to collaborate with MSD on this clinical trial, which is the first to explore the combination of an intravenously delivered oncolytic virotherapy with a checkpoint inhibitor such as KEYTRUDA in non-small cell lung and metastatic bladder cancer," said Dr Malcolm McColl, CEO and Managing Director of Viralytics. "We are pleased to have this opportunity to work with a leader in the immuno-oncology field to evaluate the potential synergy of these two novel immunotherapies in these very common cancer types."

"We believe that there may be potential benefit in combining CAVATAK with our anti-PD-1 therapy, KEYTRUDA -- which have different, yet complementary approaches to engaging the immune system to fight cancer -- and look forward to seeing results from this study," said Dr. Eric Rubin, vice president and therapeutic area head, oncology early-stage development, MSD Research Laboratories.

The phase 1b combination trial will be the second stage of Viralytics' ongoing STORM clinical trial. The first stage of this study is focusing on assessing the intravenous administration of CAVATAK as a monotherapy in late-stage solid cancer patients. Initial results indicate that multiple intravenous infusions of CAVATAK have been well tolerated and have produced potential tumour viral replication in some advanced cancer patients, with anti-tumour activity seen in some individual lesions.

The second stage of the STORM trial has been re-designed to assess the intravenous delivery of CAVATAK in combination with KEYTRUDA in patients with advanced NSCLC or metastatic bladder cancer. The trial will be an open-label, multi-centre study with dose escalation of CAVATAK in combination with fixed doses of KEYTRUDA, followed by an expansion cohort phase. The final cohort will contain approximately 80 patients, across both indications. The aim of the study is to establish a recommended dose regimen for the CAVATAK/KEYTRUDA combination and to evaluate anti-cancer activity and patient tolerability. Patient biopsies will be assessed for changes in the tumour microenvironment that may provide a further signal of activity.

Viralytics will provide CAVATAK and sponsor the study; MSD will provide KEYTRUDA and conduct biomarker analysis. The agreement includes a provision where the parties may extend the collaboration to include a potential Phase 3 clinical trial. Additional details of the collaboration were not disclosed.

Source:

Viralytics Limited

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
ASCCP voices support for 2020 ACS guidelines, recognizes the need to shift to primary HPV screening